SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 517.26 |
| Enterprise Value ($M) | n/a |
| Book Value ($M) | 516.94 |
| Book Value / Share | 2.31 |
| Price / Book | n/a |
| NCAV ($M) | 207.07 |
| NCAV / Share | 0.92 |
| Price / NCAV | n/a |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.47 |
| Return on Assets (ROA) | -0.27 |
| Return on Equity (ROE) | -0.36 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 2.43 |
| Current Ratio | 2.57 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 478.38 |
| Assets | 788.25 |
| Liabilities | 271.31 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 53.76 |
| Operating Income | -274.21 |
| Net Income | -260.17 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -267.89 |
| Cash from Investing | -55.20 |
| Cash from Financing | 230.89 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Ra Capital Management, L.p. | 1.20 | ||
| 13G/A | Glaxosmithkline Plc | 7.40 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 142,373 | 820,425 | 17.35 | |
| 216,000 | 390,384 | 55.33 | |
| 112,878 | 327,808 | 34.43 | |
| 57,133 | 220,803 | 25.88 | |
| 45,413 | 213,186 | 21.30 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| CRON – Cronos Group Inc. | CRSP – CRISPR Therapeutics AG |
| CRVS – Corvus Pharmaceuticals, Inc. | EGRX – Eagle Pharmaceuticals, Inc. |
| ELTX – Elicio Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io